| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10039668 | HBV | ENSG00000055118.18 | protein_coding | KCNH2 | No | No | 3757 | A0A090N7W1 A0A090N7X5 A0A090N8Q0 Q12809 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KCNH2 |
|---|---|
| DrugBank ID | DB00199 |
| Drug Name | Erythromycin |
| Target ID | BE0000090 |
| UniProt ID | Q12809 |
| Regulation Type | inhibitor |
| PubMed IDs | 15324906; 14674677; 24417241 |
| Citations | Du LP, Tsai KC, Li MY, You QD, Xia L: The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4771-7.@@Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW: Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem. 2003 Dec;254(1-2):1-7.@@Crumb WJ Jr: Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels. Br J Pharmacol. 2014 Apr;171(7):1668-75. doi: 10.1111/bph.12575. |
| Groups | Approved; Investigational; Vet_approved |
| Direct Classification | Aminoglycosides |
| SMILES | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O |
| Pathways | Erythromycin Action Pathway |
| PharmGKB | PA449493 |
| ChEMBL | CHEMBL532 |
